04:51 PM EDT, 08/13/2025 (MT Newswires) -- Aptose Biosciences ( APTOF ) Wednesday after-trade reported second-quarter net loss narrowed slightly.

The company said its lost US$7.04 million, or US$2.76 per share, in the period US$7.24 million, or US$12.99 per share, in the prior year period.

It reported no revenue and ended the quarter with $1.3 million of cash on hand, down from $6.71 million a year earlier.

Aptose is developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML).

The company's shares closed up $0.01 to $1.72 on the Toronto Stock Exchange.